|Bid||8.56 x 1000|
|Ask||8.57 x 1000|
|Day's Range||8.22 - 8.79|
|52 Week Range||2.43 - 22.95|
|Beta (5Y Monthly)||2.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.37|
Shares of Tilray were climbing Wednesday morning after the cannabis company said it had entered into a co-promotion agreement with German pharmaceutical firm Hormosan. Hormosan will support Tilray in its marketing and sales activities of full spectrum cannabis extract in Germany, Tilray said in a statement, and the two companies will use their expertise to expand Tilray's presence in the German market.
Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.